welcome to HCM!
In most cases, the treatment for diffuse large B-cell lymphoma
(DLBCL) is chemotherapy
, usually with a regimen of 4 drugs cyclophosphamide
, vincristine, and prednisone, plus the monoclonal antibody rituximab . This regimen, known as R-CHOP, is usually given for about 6 months.
Rituximab is a type of biological therapy . Rituximab targets a protein known as CD20. CD20 is found on white blood cells called B cells. It is the B cells that are cancerous in the most common type of non Hodgkin lymphoma
. Rituximab attaches itself to the B cells and marks them. The cells of the immune system recognise the marked cells and kill them.
An increased risk of getting an infection from a drop in white blood cells – it is harder to fight infections and patient can become very ill.
DLBCL can be cured in about half of all patients, but the stage of the disease and the IPI score can have a large effect on this. Patients with lower disease stages have better survival rates, as do patients with lower IPI scores.
hope this helps!take care!